GSK’s Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat

기사 요약

GSK beat Q3 analyst consensus with $1.47 adjusted EPS and $11.95 billion revenue, as specialty drugs offset vaccine drops. 2026 outlook reaffirmed.